Physician profile
Johny Abraham
NPI 1548724578
$3,045.06
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $635 · 2022: $1,028 · 2023: $1,308 · 2024: $73.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $809.37 | 2021-2024 | Mounjaro, Jardiance |
| Abbvie INC. | $720.28 | 2021-2024 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $580.92 | 2021-2023 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $141.56 | 2023 | |
| Alkermes, INC. | $120.99 | 2022-2023 | Aristada, Lybalvi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.80 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $88.07 | 2022-2023 | Verquvo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.71 | 2022 | |
| Novartis Pharmaceuticals Corporation | $77.71 | 2022-2023 | |
| Glaxosmithkline, LLC. | $73.11 | 2021-2023 | Trelegy Ellipta |
| Indivior INC. | $59.44 | 2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $58.66 | 2022-2023 | Eliquis |
| Pfizer INC. | $51.34 | 2022-2023 | |
| Novo Nordisk INC | $36.14 | 2023 | Rybelsus |
| Otsuka America Pharmaceutical, INC. | $27.44 | 2023 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $21.52 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johny Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.